Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

被引：1

作者：

Papadimitrakopoulou, Vassiliki ^{[1
]}

Redman, Mary ^{[2
]}

Gandara, David R. ^{[3
]}

Hirsch, Fred R. ^{[4
]}

Mack, Philipp ^{[5
]}

Borghaei, Hossein ^{[6
]}

Langer, Corey ^{[7
]}

Wade, James ^{[8
]}

Edelman, Martin ^{[9
]}

Albain, Kathy ^{[10
]}

Lara, Primo ^{[5
]}

Aggarwal, Charu ^{[11
]}

Socinski, Mark ^{[12
]}

Gettinger, Scott ^{[13
]}

Bazhenova, Lyudmila ^{[14
]}

Malik, Shakun ^{[15
]}

Miller, Vincent ^{[16
]}

Mcdonough, Shannon ^{[17
]}

Sigal, Ellen V. ^{[2
]}

Kelly, Karen ^{[18
]}

Herbst, Roy ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Friends Canc Res, Washington, DC USA

[3] UC Davis Comprehens Canc Ctr, Div Hem Oncol, Sacramento, CA USA

[4] Univ Colorado, Ctr Canc, Other, Aurora, CO USA

[5] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[6] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] Univ Penn Hlth Syst, Hematol Oncol, Philadelphia, PA USA

[8] Heartland Ncorp, Decatur, IL USA

[9] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA

[10] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Div Hematol Oncol, Maywood, IL USA

[11] Univ Penn, Hematol Oncol, Philadelphia, PA 19104 USA

[12] Univ Pittsburgh, Med, Pittsburgh, PA USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] NCI, Ctep, NIH, Rockville, MD USA

[16] Fdn Med Inc, Clin Dev, Cambridge, MA USA

[17] Swog Stat Ctr, Seattle, WA USA

[18] UC Davis Comprehens Canc Ctr, Hematol Oncol, Sacramento, CA USA

[19] Yale Canc Ctr, Med Oncol, New Haven, CT USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

genomic screening; umbrella trial; S1400; Squamous cell lung cancer;

D O I：

10.1016/j.jtho.2016.11.513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA16.10

引用

页码：S439 / S440

页数：2

共 47 条

[21] Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.
Gonzalez-Kozlova, Edgar
Huang, Hsin-Hui
Redman, Mary Weber
Herbst, Roy S.
Gettinger, Scott N.
Bazhenova, Lyudmila
Xie, Hui
Patel, Manishkumar
Nie, Kai
Harris, Jocelyn
Argueta, Kimberly
Cerami, Ethan
Hong, Joyce
Biswas, Roshni
Van Nostrand, Stephen
Kelly, Karen
Moravec, Radim
Del Valle, Diane
Kim-Schulze, Seunghee
Gnjatic, Sacha
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer
Gonzalez-Kozlova, Edgar
Huang, Hsin-Hui
Redman, Mary
Herbst, Roy
Gettinger, Scott
Bazhenova, Luda
Xie, Hui
Patel, Manishkumar
Nie, Kai
Harris, Jocelyn
Argueta, Kimberly
Kelly, Karen
Cerami, Ethan
Lindsay, James
Yu, Joyce
Biswas, Roshni
Van Nostrand, Stephen
Moravec, Radim
Del Valle, Diane Marie
Kim-schulze, Seunghee
Gnjatic, Sacha
CANCER RESEARCH, 2022, 82 (12)
[23] Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Gettinger, Scott N.
Redman, Mary W.
Bazhenova, Lyudmila
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence H.
Bradley, Jeffrey D.
Stinchcombe, Thomas E.
Leighl, Natasha B.
Ramalingam, Suresh S.
Tavernier, Susan S.
Yu, Hui
Unger, Joseph M.
Minichiello, Katherine
Highleyman, Louise
Papadimitrakopoulou, Vassiliki A.
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
JAMA ONCOLOGY, 2021, 7 (09) : 1368 - 1377
[24] Lung cancer screening updates: Impact of 2023 American Cancer Society's guidelines for lung cancer screening
Rashidi, Ali
Kao, Raymond
Echeverria, Richard
Sadigh, Gelareh
CLINICAL IMAGING, 2024, 113
[25] Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Parra, Edwin Roger
Zhang, Jiexin
Duose, Dzifa Yawa
Gonzalez-Kozlova, Edgar
Redman, Mary W.
Chen, Hong
Manyam, Ganiraju C.
Kumar, Gayatri
Zhang, Jianhua
Song, Xingzhi
Lazcano, Rossana
Marques-Piubelli, Mario L.
Laberiano-Fernandez, Caddie
Rojas, Frank
Zhang, Baili
Taing, Len
Jhaveri, Aashna
Geisberg, Jacob
Altreuter, Jennifer
Michor, Franziska
Provencher, James
Yu, Joyce
Cerami, Ethan
Moravec, Radim
Kannan, Kasthuri
Luthra, Rajyalakshmi
Alatrash, Gheath
Huang, Hsin-Hui
Xie, Hui
Patel, Manishkumar
Nie, Kai
Harris, Jocelyn
Argueta, Kimberly
Lindsay, James
Biswas, Roshni
Van Nostrand, Stephen
Kim-Schulze, Seunghee
Gray, Jhanelle E.
Herbst, Roy S.
Wistuba, Ignacio I.
Gettinger, Scott
Kelly, Karen
Bazhenova, Lyudmila
Gnjatic, Sacha
Lee, J. Jack
Zhang, Jianjun
Haymaker, Cara
CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1655 - 1668
[26] SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
Borghaei, Hossein
Redman, Mary W.
Kelly, Karen
Waqar, Saima N.
Robert, Francisco
Kiefer, Gauri J.
Stella, Philip J.
Minichiello, Katherine
Gandara, David R.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki A.
CLINICAL LUNG CANCER, 2021, 22 (03) : 178 - 186
[27] A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Substudy SWOG S1400A
Papadimitrakopoulou, V.
Redman, M. W.
Borghaei, H.
Waqar, S. N.
Robert, F.
Kiefer, G. J.
McDonough, S.
Herbst, R. S.
Kelly, K.
Gandara, D. R.
ANNALS OF ONCOLOGY, 2017, 28
[28] A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).
Owonikoko, Taofeek Kunle
Redman, Mary Weber
Byers, Lauren Averett
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence Howard
Bradley, Jeffrey D.
Stinchcombe, Tom
Leighl, Natasha B.
Al Baghdadi, Tareq
Lara, Primo
Miao, Jieling
Kelly, Karen
Ramalingam, Suresh S.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki
Gandara, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
Waqar, Saiama N.
Redman, Mary W.
Arnold, Susanne M.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence H.
Gandara, David R.
Stinchcombe, Thomas E.
Leighl, Natasha B.
Ramalingam, Suresh S.
Tanna, Saloni H.
Raddin, Ryan S.
Minichiello, Katherine
Bradley, Jeffrey D.
Kelly, Karen
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki A.
CLINICAL LUNG CANCER, 2021, 22 (03) : 170 - 177
[30] A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub -study SWOG S1400C.
Edelman, Martin J.
Redman, Mary Weber
Albain, Kathy S.
McGary, Eric C.
Rafique, Norman
Petro, Daniel P.
Waqar, Saiama Naheed
Miao, Jieling
Griffin, Katie
Papadimitrakopoulou, Vassiliki
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →